Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 1. Analyst Marc Goodman from Leerink Partners maintained a Buy rating on the stock and has a $260.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Marc Goodman has given his Buy rating due to a combination of factors, including Biogen’s strong performance in the first quarter of 2025 and positive outlook on international sales. The company showed resilience in its Spinraza product and positive developments in Skyclarys and Leqembi outside the United States. This international strength is significant as a large portion of Biogen’s revenue is expected to come from outside the U.S. in 2024.
Despite some challenges in the U.S. market, particularly with Skyclarys and Leqembi, Goodman remains optimistic about future growth. The anticipated approval of new diagnostics and treatments for Alzheimer’s disease, along with promising pipeline developments like BIIB080 and Litifilimab, suggest potential for significant growth. This long-term potential, along with management’s strategic commentary, supports the Buy rating.
In another report released on May 2, Oppenheimer also maintained a Buy rating on the stock with a $205.00 price target.
BIIB’s price has also changed moderately for the past six months – from $173.790 to $120.930, which is a -30.42% drop .